Kalle Sigfridsson

Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development

A. Lundqvist, K. Sigfridsson, Kalle Sigfridsson, 2009, Drug development and industrial pharmacy.

Plastocyanin, an electron-transfer protein

K. Sigfridsson, Kalle Sigfridsson, 1998, Photosynthesis Research.

A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.

K. Sigfridsson, Kalle Sigfridsson, Sara Forssén, 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development

Anna Nordmark, A. Lindahl, Anders Lindahl, 2011, Drug development and industrial pharmacy.

Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.

Susanne Winiwarter, Johan Ulander, Anna Pettersen, 2015, Journal of medicinal chemistry.

Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound.

H. Zachrisson, J. Björkman, K. Sigfridsson, 2011, Journal of pharmaceutical sciences.

Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release

Hanna Rydberg, Hanna A. Rydberg, K. Sigfridsson, 2019, Drug development and industrial pharmacy.